Bioimpedance analysis, metabolic effects and safety of the association berberis aristataisilybum marianum: A 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes

G. Guarino, F. Strollo, Lucia Carbone, T. Della Corte, M. Letizia, G. Marino, S. Gentile

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Berberine, a quaternary isoquinoline alkaloid present in Berberis aristata, is well known in terms of cholesterol-lowering, hypoglycemic, and insulin sensitizing effects. Because of its low oral bioavailability, to improve intestinal absorption it has been recently combined with Silymarin (Silybum marianum). The aim of our placebo controlled study was to evaluate the effects of its association with Silymarin on abdominal fat in overweight/obese patients with type 2 diabetes mellitus (T2DM). To do so, 136 obese subjects with T2DM and metabolic syndrome were analyzed for fasting blood glucose and insulin, Insulin Resistance index according to the Homeostatic Model Assessment (HOMA-R), total, HDL and LDL cholesterol, triglycerides, uric acid, BMI, waist circumference, waist to hip ratio and underwent bioelectrical impedance to assess % abdominal fat. All the above-mentioned parameters, as recorded at enrollment, after 6 months and at the end of the study, had significantly improved in the BBR-treated group in respect to baseline and to the control group. A validated national cardiovascular risk score also improved significantly after BBR treatment in respect to placebo. Our results point to a clinically significant effect in obese people with T2DM and metabolic syndrome. Moreover, for the first time, they provide evidence of a significant uric acid lowering activity as an additive beneficial effect of the association BBR + Silymarin.

Original languageEnglish (US)
Pages (from-to)495-502
Number of pages8
JournalJournal of Biological Regulators and Homeostatic Agents
Volume31
Issue number2
StatePublished - Apr 1 2017
Externally publishedYes

Fingerprint

Berberis
Milk Thistle
Type 2 Diabetes Mellitus
Abdominal Fat
Placebos
Uric Acid
Safety
Insulin
Berberine
Waist-Hip Ratio
Intestinal Absorption
Waist Circumference
Electric Impedance
Alkaloids
Hypoglycemic Agents
LDL Cholesterol
HDL Cholesterol
Biological Availability
Insulin Resistance
Blood Glucose

Keywords

  • Berberine-silymarin
  • Bioimpedance
  • Body composition
  • Metabolic syndrome
  • Nutraceutical
  • T2DM

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Physiology
  • Immunology
  • Oncology
  • Endocrinology
  • Physiology (medical)
  • Cancer Research

Cite this

Bioimpedance analysis, metabolic effects and safety of the association berberis aristataisilybum marianum : A 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes. / Guarino, G.; Strollo, F.; Carbone, Lucia; Della Corte, T.; Letizia, M.; Marino, G.; Gentile, S.

In: Journal of Biological Regulators and Homeostatic Agents, Vol. 31, No. 2, 01.04.2017, p. 495-502.

Research output: Contribution to journalArticle

@article{4ca80f1e2f8c4bb287358f950733b280,
title = "Bioimpedance analysis, metabolic effects and safety of the association berberis aristataisilybum marianum: A 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes",
abstract = "Berberine, a quaternary isoquinoline alkaloid present in Berberis aristata, is well known in terms of cholesterol-lowering, hypoglycemic, and insulin sensitizing effects. Because of its low oral bioavailability, to improve intestinal absorption it has been recently combined with Silymarin (Silybum marianum). The aim of our placebo controlled study was to evaluate the effects of its association with Silymarin on abdominal fat in overweight/obese patients with type 2 diabetes mellitus (T2DM). To do so, 136 obese subjects with T2DM and metabolic syndrome were analyzed for fasting blood glucose and insulin, Insulin Resistance index according to the Homeostatic Model Assessment (HOMA-R), total, HDL and LDL cholesterol, triglycerides, uric acid, BMI, waist circumference, waist to hip ratio and underwent bioelectrical impedance to assess {\%} abdominal fat. All the above-mentioned parameters, as recorded at enrollment, after 6 months and at the end of the study, had significantly improved in the BBR-treated group in respect to baseline and to the control group. A validated national cardiovascular risk score also improved significantly after BBR treatment in respect to placebo. Our results point to a clinically significant effect in obese people with T2DM and metabolic syndrome. Moreover, for the first time, they provide evidence of a significant uric acid lowering activity as an additive beneficial effect of the association BBR + Silymarin.",
keywords = "Berberine-silymarin, Bioimpedance, Body composition, Metabolic syndrome, Nutraceutical, T2DM",
author = "G. Guarino and F. Strollo and Lucia Carbone and {Della Corte}, T. and M. Letizia and G. Marino and S. Gentile",
year = "2017",
month = "4",
day = "1",
language = "English (US)",
volume = "31",
pages = "495--502",
journal = "Journal of Biological Regulators and Homeostatic Agents",
issn = "0393-974X",
publisher = "Biolife SAS",
number = "2",

}

TY - JOUR

T1 - Bioimpedance analysis, metabolic effects and safety of the association berberis aristataisilybum marianum

T2 - A 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes

AU - Guarino, G.

AU - Strollo, F.

AU - Carbone, Lucia

AU - Della Corte, T.

AU - Letizia, M.

AU - Marino, G.

AU - Gentile, S.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Berberine, a quaternary isoquinoline alkaloid present in Berberis aristata, is well known in terms of cholesterol-lowering, hypoglycemic, and insulin sensitizing effects. Because of its low oral bioavailability, to improve intestinal absorption it has been recently combined with Silymarin (Silybum marianum). The aim of our placebo controlled study was to evaluate the effects of its association with Silymarin on abdominal fat in overweight/obese patients with type 2 diabetes mellitus (T2DM). To do so, 136 obese subjects with T2DM and metabolic syndrome were analyzed for fasting blood glucose and insulin, Insulin Resistance index according to the Homeostatic Model Assessment (HOMA-R), total, HDL and LDL cholesterol, triglycerides, uric acid, BMI, waist circumference, waist to hip ratio and underwent bioelectrical impedance to assess % abdominal fat. All the above-mentioned parameters, as recorded at enrollment, after 6 months and at the end of the study, had significantly improved in the BBR-treated group in respect to baseline and to the control group. A validated national cardiovascular risk score also improved significantly after BBR treatment in respect to placebo. Our results point to a clinically significant effect in obese people with T2DM and metabolic syndrome. Moreover, for the first time, they provide evidence of a significant uric acid lowering activity as an additive beneficial effect of the association BBR + Silymarin.

AB - Berberine, a quaternary isoquinoline alkaloid present in Berberis aristata, is well known in terms of cholesterol-lowering, hypoglycemic, and insulin sensitizing effects. Because of its low oral bioavailability, to improve intestinal absorption it has been recently combined with Silymarin (Silybum marianum). The aim of our placebo controlled study was to evaluate the effects of its association with Silymarin on abdominal fat in overweight/obese patients with type 2 diabetes mellitus (T2DM). To do so, 136 obese subjects with T2DM and metabolic syndrome were analyzed for fasting blood glucose and insulin, Insulin Resistance index according to the Homeostatic Model Assessment (HOMA-R), total, HDL and LDL cholesterol, triglycerides, uric acid, BMI, waist circumference, waist to hip ratio and underwent bioelectrical impedance to assess % abdominal fat. All the above-mentioned parameters, as recorded at enrollment, after 6 months and at the end of the study, had significantly improved in the BBR-treated group in respect to baseline and to the control group. A validated national cardiovascular risk score also improved significantly after BBR treatment in respect to placebo. Our results point to a clinically significant effect in obese people with T2DM and metabolic syndrome. Moreover, for the first time, they provide evidence of a significant uric acid lowering activity as an additive beneficial effect of the association BBR + Silymarin.

KW - Berberine-silymarin

KW - Bioimpedance

KW - Body composition

KW - Metabolic syndrome

KW - Nutraceutical

KW - T2DM

UR - http://www.scopus.com/inward/record.url?scp=85026537362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026537362&partnerID=8YFLogxK

M3 - Article

C2 - 28685558

AN - SCOPUS:85026537362

VL - 31

SP - 495

EP - 502

JO - Journal of Biological Regulators and Homeostatic Agents

JF - Journal of Biological Regulators and Homeostatic Agents

SN - 0393-974X

IS - 2

ER -